Delving into the Latest Updates on The Methodist Hospitals, Inc. with Synapse

概览

疾病领域	数量

肿瘤	9
免疫系统疾病	2
血液及淋巴系统疾病	2
神经系统疾病	1

排名前五的药物类型	数量

自体CAR-T	4
CAR-T	3
小分子化药	1
基因疗法	1

排名前五的靶点	数量

HER2(受体蛋白酪氨酸激酶 erbB-2)	3
HIV integrase(HIV整合酶)	1
IL-12(白细胞介素-12)	1
CD30(肿瘤坏死因子受体超家族成员8)	1
κ light chain of human immunoglobulins(免疫球蛋白轻链κ)	1

关联

10

项与 The Methodist Hospitals, Inc. 相关的药物

Hydroxytyrosol

靶点

HIV integrase

作用机制

HIV-1 integrase抑制剂

在研机构

University of South Alabama [+1]

原研机构

The Methodist Hospitals, Inc.

在研适应症

乳腺癌 [+1]

非在研适应症-

最高研发阶段临床3期

首次获批国家/地区-

首次获批日期-

IL-12 gene therapy(The Methodist Hospitals, Inc.)

靶点

IL-12

作用机制

IL-12刺激剂

在研机构

The Methodist Hospitals, Inc.

原研机构

The Methodist Hospitals, Inc.

在研适应症

三阴性乳腺癌

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

GLYCAR T cell therapy(Baylor College of Medicine)

靶点

GPC3

作用机制

GPC3调节剂

在研机构

Baylor College of Medicine [+1]

原研机构

Baylor College of Medicine

在研适应症

GPC3阳性肝细胞癌 [+1]

非在研适应症-

最高研发阶段临床1期

首次获批国家/地区-

首次获批日期-

100 项与 The Methodist Hospitals, Inc. 相关的临床结果

登录后查看更多信息

0 项与 The Methodist Hospitals, Inc. 相关的专利（医药）

登录后查看更多信息

39

项与 The Methodist Hospitals, Inc. 相关的文献（医药）

2022-07-01·Journal of Infusion Nursing

Keeping Patients Safer: Reviewing Predictors of Success and Failure of Short Peripheral Intravenous Catheters

Article

作者: Scott, Nancy ; DeVries, Michelle

In 2014, a large urban community hospital adopted protected clinical indication practices as a quality improvement project. It then undertook a research study to examine bedside practices with short peripheral catheters, which included direct observation at the bedside once weekly for 6 months. A total of 4305 catheters were observed and remained in place for a total of 23 423 days. Fifty six percent of devices remained in place beyond 96 hours. The overall rate of peripheral bloodstream infection in patients enrolled in the study was 0.12/1000 peripheral intravenous days. Significant differences were noted based on which department placed the catheter, as well as which department cared for the patient during hospitalization. Patients admitted to step-down critical care units had the highest completion of therapy rates; however, those being cared for in medical/surgical units had the best outcomes. Devices placed in the emergency department had a higher successful dwell rate than those placed in critical care units. Twenty-gauge catheters were found to have the highest successful dwell rate, as well as insertion sites that were observed to be within normal limits during the weekly observation. Dressings that were noted to be clean, dry, and intact had a stronger association with completion of therapy than those that were not fully intact. Emphasis was placed on ensuring consistent practices with insertion, care, and maintenance, which contributed to more consistent outcomes between settings that insert, care for, and maintain devices. Nonmodifiable risk factors may remain.

2022-01-01·Multiple Sclerosis and Related Disorders3区 · 医学

B-cell depleters attenuate the humoral response to SARS-CoV-2 vaccines in multiple sclerosis patients: A case-control study

3区 · 医学

Article

作者: Conte, William L

BACKGROUNDB-cell depleting agents are FDA approved for the treatment of RRMS (ocrelizumab (OCR) and ofatumumab (OFA)) and PPMS (OCR). In the case of OCR, prior studies have raised concerns about patients' ability to form antibodies in response to various antigens, especially SARS-CoV-2. In addition, emerging data have shown an attenuated humoral response to vaccines against SARS-CoV-2. The objective of this study is to determine whether b-cell depleters or sphingosine 1-phosphate (S1P) modulators attenuate the antibody response to various SARS-CoV-2 vaccines in patients with MS as compared with other MS disease modifying therapies (DMTs).METHODSThis is a case-control study looking at the odds of developing antibodies to three SARS-CoV-2 vaccines (Pfizer-BioNTech, Moderna, and Johnson & Johnson) in patients treated with b-cell depleters or S1P modulators versus other disease modifying therapies. Patients were recruited at the Comprehensive MS Center at Methodist Hospitals. Patients who did not have a prior COVID-19 infection and received one of the three vaccines were tested for antibodies against the SARS-CoV-2 spike protein (Labcorp, semi-quantitative total antibody) at least two weeks following the final dose of the vaccine. Groups (B-cell, S1P modulators, other DMT, and no DMT) were compared on antibody level. The main outcome was whether or not a humoral response was detected by antibody testing. Dichotomous antibody response was tested using logistic regression models, and the quantitative response was tested using ANCOVA adjusted for covariates (age, sex, race, MS type, disease duration, vaccine, and lymphocyte count). P-values <0.05 were considered significant.RESULTSSixty-seven patients were enrolled in the study, with 17 on OCR, 3 on OFA, 12 on S1P modulators, 29 on other DMT, and 6 not currently on any DMT. Patients who received OCR or OFA had decreased odds of forming antibodies (OR 0.031, p < 0.001, 95% CI (0.003-0.268)). Patients who received S1P modulators did not have decreased odds of forming antibodies (OR 0.413, p = 0.413, 95% CI (0.28-21.7). However, when analyzing the antibody response as a continuous variable, patients on S1P modulators showed lower absolute levels of antibodies (p = 0.024).CONCLUSIONSPatients who received B-cell depleters within the prior 6 months of SARS-CoV-2 vaccination had decreased odds of developing antibodies compared with other DMTs. In line with other similar research, this suggests that b-cell depleters attenuate the antibody response to SARS-CoV-2 vaccines. Although S1P modulators had an attenuation of the absolute antibody level, the odds of being negative did not differ from those on other DMTs.

2021-09-01·Air Medical Journal

Comparison of Hyperangulated and Standard Geometry Video Laryngoscopy Tracheal Intubation for Prehospital Care in a Manikin: A Randomized Controlled Crossover Trial

Article

作者: Galgon, Richard ; Lepa, Nicholas ; Schroeder, Kristopher M ; Jennett, Brian ; Emmerich, Kevin ; Cathers, Andrew ; Steuerwald, Michael

OBJECTIVEThe purpose of this study was to investigate the efficacy of hyperangulated video laryngoscopy (HAVL) versus standard geometry video laryngoscopy (SGVL) in the simulated prehospital environment using a manikin. There is consensus that video laryngoscopy (VL) can be very useful in the emergency department when difficult intubations are predicted. Emergency medical service (EMS) providers are also often faced with difficult, rapidly deteriorating airway management situations that not only involve patient and operator factors but also include challenging unique environmental factors, such as nonoptimized positions in transport vehicles (eg, helicopters and ambulances) or at ground level or entrapped positions. To our knowledge, there has never been a study purposefully investigating the efficacy of hyperangulated geometry versus standard geometry VL techniques in the prehospital environment.METHODSA single-center, randomized controlled crossover trial was performed using attending physician helicopter EMS providers. Physicians were randomized to perform 5 HAVL or SGVL intubations followed by the subsequent technique. Intubations were performed on ground level and then repeated in the helicopter with the first location also randomized. A manikin airway management trainer was used to simulate intubation in each environment. The time to intubation (primary outcome) as well as first-pass success and the Cormack-Lehane view were recorded for each attempt. Qualitative data were also obtained for physician preference and perceived difficulty.RESULTSThere was no statistically significant difference in the time to intubation with HAVL versus SGVL (ground: 15.02 vs. 14.88 seconds, P = .86; helicopter: 16.11 vs. 16.14 seconds, P = .93). First-pass success was 100% for both techniques in both scenarios. More Grade 1 views were obtained with HAVL (147/150 vs. 134/150). Moreover, most physicians preferred HAVL overall and felt that HAVL required less force (9/15 grounded manikin and 10/15 helicopter manikin) and led to the best chance for first-pass success (11/15 grounded manikin and 10/15 helicopter manikin).CONCLUSIONThe results of this study are limited because of the static and highly favorable anatomy of a manikin versus the variability and often difficult anatomy of individual patients. Our results suggest that both techniques are efficacious when the patient is both on the ground or in the helicopter, although provider preference does seem to vary.

100 项与 The Methodist Hospitals, Inc. 相关的药物交易

登录后查看更多信息

100 项与 The Methodist Hospitals, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月22日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床1期

7

1

临床2期

临床3期

1

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Hydroxytyrosol ( HIV integrase )	乳腺癌更多	临床3期
IL-12 gene therapy(The Methodist Hospitals, Inc.) ( IL-12 )	三阴性乳腺癌更多	临床2期
Autologous-HER2-specific-T-cells(Baylor College of Medicine) ( HER2 )	肉瘤更多	临床1期
Kappa-CD28-T-cells(Baylor College of Medicine) ( κ light chain of human immunoglobulins )	多发性骨髓瘤更多	临床1期
TGFBeta-resistant-HER2-EBV-CTLs(Baylor College of Medicine) ( HER2 )	肿瘤更多	临床1期